Editas Medicine Announces Nomination of EDIT-401 as Lead In Vivo Development Candidate for LDL-C Reduction, Aiming for Human Data by 2026
Editas Medicine Inc. has nominated EDIT-401 as its lead in vivo development candidate for reducing LDL cholesterol levels. In non-human primate studies, a single dose of EDIT-401 resulted in about a 90% reduction in mean LDL-C levels. The company aims to present human proof-of-concept data by the end of 2026 and has secured operational funding until Q2 2027. A webinar on EDIT-401 is also scheduled.
Editas Medicine Inc., a gene editing company, has announced the nomination of EDIT-401 as their lead in vivo development candidate. EDIT-401 is an experimental therapy aimed at significantly reducing LDL cholesterol (LDL-C) levels. In studies conducted on non-human primates, a single dose of EDIT-401 achieved an approximate 90% reduction in mean LDL-C levels. The company is planning to present human proof-of-concept data by the end of 2026. Editas Medicine maintains a strong cash position, with operational funding secured until the second quarter of 2027. A company-sponsored webinar on EDIT-401 is scheduled. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9521261-en) on September 02, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
